Autoimmune diseases: Considering their dual roles in autoimmune diseases like asthma and inflammatory bowel disease, such Blimp-1-targeted therapies may decrease inflammation and oxidative stress simultaneously. This evidence concerns the gene PRDM1 and autoimmune disease.